GSK690693

Catalog No. A11030

GSK690693是一种新型的ATP竞争性低纳摩尔泛Akt激酶抑制剂（IC50值分别为Akt1、2和3的2、13和9 nM）。

Product Citations

Khan MI, .et al. Thalidomide attenuates development of m0rphine dependence in mice by inhibiting PI3K/Akt and nitric oxide signaling pathways, Prog Neuropsychopharmacol Biol Psychiatry, 2018, Mar 2;82:39-48 PMID: 9223784

Technical details

Catalog Num	A11030
M. Wt	425.5
Formula	C21H27N7O3
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	937174-76-0
Synonyms	GSK-690693
SMILES	CCN1C2=C(C(=NC=C2OC[C@H]3CCCNC3)C#CC(C)(C)O)N=C1C4=NON=C4N

Biological Activity

GSK690693是一种新型的ATP竞争性低纳摩尔泛Akt激酶抑制剂（IC50值分别为Akt1、2和3的2、13和9 nM）。

Targets

Target	Value
Akt1	IC50: 2nM
PKCη	IC50: 2nM
PKCθ	IC50: 2nM
PrkX	IC50: 5nM
Akt3	IC50: 9nM
Akt2	IC50: 13nM
PKCδ	IC50: 14nM
PKCβ	IC50: 19nM
PKCε	IC50: 21nM
PKA	IC50: 24nM
PKG1β	IC50: 33nM

Solubility *

In vitro (25°C)	DMSO	36 mg/mL (84.61 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	5% DMSO+40%PEG300+5% tween80+50% H2O	2 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	23.5 mL	117.51 mL	235.02 mL
0.5 mM	4.7 mL	23.5 mL	47 mL
1 mM	2.35 mL	11.75 mL	23.5 mL
5 mM	0.47 mL	2.35 mL	4.7 mL

*The above data is based on the productmolecular weight 425.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.